Altasciences Wins 2025 CDMO Leadership Award for Small Molecule Dosage Forms
Altasciences Wins 2025 CDMO Leadership Award for Small Molecule Dosage Forms Altasciences, a recognized leader in contract development and manufacturing (CDMO) services, has been honored with the 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This…
CRISPR Cas9 Market Poised for Rapid Growth with Gene Therapy Advances – 2024 Report
CRISPR Cas9 Market Set for Exponential Growth with Gene Therapy Advancements The latest “CRISPR Cas9 Market” report has been added to ResearchAndMarkets.com’s offerings, highlighting the transformative potential of CRISPR/Cas9 technology in medicine and biotechnology. This breakthrough gene-editing tool is set…
Cancer ADC Market to Grow by $40B by 2030 – Report
Global Cancer Antibody Drug Conjugates Market Poised for $40 Billion Growth by 2030 The global market for cancer antibody-drug conjugates (ADCs) is experiencing rapid growth, with projections indicating an increase of $40 billion between 2023 and 2030. According to the…
Bristol Myers Squibb Gets CHMP Nod for Perioperative Opdivo in Resectable NSCLC
Bristol Myers Squibb’s Opdivo-Based Perioperative Regimen Receives Positive CHMP Opinion for Resectable NSCLC Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive…
Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis
Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis 4Moving Biotech (4MB), a pioneering biotechnology company and a spin-off of 4P-Pharma, has received authorization from Health Canada to initiate its Phase 2a INFLAM MOTION clinical trial. This study…
Curatis Achieves 30% Sales Growth & Expands C-PTBE-01 Patient Reach
Curatis Achieves 30% Sales Growth & Expands C-PTBE-01 Patient Reach Curatis Holding AG (SIX:CURN, ‘Curatis’) has reported strong business performance in 2024, achieving business revenues of CHF 6.9 million, with Curatis AG contributing to these figures for only eight months.…
Celltrion’s Remdantry™ Set for Canada Launch on April 1, 2025
Celltrion’s Remdantry™ Set for Canada Launch on April 1, 2025 Celltrion, Inc., a global biopharmaceutical leader, has announced that its biosimilar Remdantry™ will be available in Canada starting April 1, 2025. Previously marketed under the name Inflectra®, Remdantry™ represents the…
Invivoscribe Registers LeukoStrat® CDx FLT3 Assay in UK & Switzerland
Invivoscribe Registers LeukoStrat® CDx FLT3 Assay in UK & Switzerland Invivoscribe, a global leader in precision diagnostics, has announced the successful registration of its LeukoStrat CDx FLT3 Mutation Assay in both the United Kingdom (UK) and Switzerland. This critical milestone…
Dial A Vet Expands to Canada, USA, and UK, Making Veterinary Care More Affordable
Dial A Vet Expands to Canada, USA, and UK, Making Veterinary Care More Affordable Dial A Vet Expands Globally: Bringing Affordable Veterinary Care to Canada, USA, and UK Dial A Vet, Australia’s premier telehealth veterinary service, has announced its global…
Sweden Takes Key Step Toward a Smoke-Free World with New Policy
Sweden Takes Key Step Toward a Smoke-Free World with New Policy Sweden has officially enshrined tobacco harm reduction in its public health policy, becoming the first nation to demonstrate that this approach is the most effective pathway to a smoke-free…
Xcell Biosciences & Royal Perth Hospital Partner on Next-Gen Automated TIL Manufacturing
Xcell Biosciences and Royal Perth Hospital Partner to Develop Next-Generation Automated TIL Manufacturing Workflow Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a leading platform company specializing in cell and gene therapy applications, has announced a…
FDA Approves Blujepa (Gepotidacin) for Uncomplicated UTIs in Patients 12+
FDA Approves Blujepa (Gepotidacin) for Uncomplicated UTIs in Patients 12+ GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in female adults…